Showing results (2011-2020 of 2,164) with videos related to

Sort By:
Pageof 217
Journal of Medicinal Chemistry|February 9, 2008
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugsJian-Xin Duan, Hailong Jiao, Jacob Kaizerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeysF M Uckun, Y Yanishevski, N Tumer, et al.
Nature Communications|June 19, 2026
Single-cell RNA sequencing profiles drug activity within spatially engineered 3D culturesJessica J King, Alireza Mowla, Jessica A Kretzmann, et al.
Hypertension (Dallas, Tex. : 1979)|November 9, 2016
Increased Aortic Calcification Is Associated With Arterial Stiffness Progression in Multiethnic Middle-Aged MenJingchuan Guo, Akira Fujiyoshi, Bradley Willcox, et al.
JCI Insight|December 27, 2016
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapyJiha Kim, Pedro Correa de Sampaio, Donna Marie Lundy, et al.
Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.
The New England Journal of Medicine|October 13, 2006
Microscopic-observation drug-susceptibility assay for the diagnosis of TBDavid A J Moore, Carlton A W Evans, Robert H Gilman, et al.
Journal of the American Society of Hypertension : JASH|September 27, 2016
Orthostatic changes in systolic blood pressure among SPRINT participants at baselineRaymond R Townsend, Tara I Chang, Debbie L Cohen, et al.
The British Journal of Nutrition|August 18, 2011
Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1Sunghee Lee, J David Curb, Takashi Kadowaki, et al.
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Pageof 217